Mark D. Rothmann

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Martin H. Cohen, Grant Williams, John R. Johnson et al. · PubMed · 2002 · 469 citations

Design and analysis of non‐inferiority mortality trials in oncology

Mark D. Rothmann, Ning Li, Gang Chen et al. · Statistics in Medicine · 2002 · 241 citations

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Mark D. Rothmann, Jogarao Gobburu, Gabriel J. Robbie et al. · PubMed · 2002 · 240 citations

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Thomas M. Herndon, Albert Deisseroth, Edvardas Kaminskas et al. · Clinical Cancer Research · 2013 · 240 citations

Hematological Malignancy, Thrombosis, Translational Medicine +15

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 207 citations

Lymphoid Neoplasia, Translational Medicine, Hodgkin Lymphoma +12